CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
At this year’s International Headache Congress, migraine specialists from around the world gathered in São Paulo, Brazil (10-13 September), to discuss latest research.
Further evidence that fewer patients are likely to meet recent International Headache Society (IHS) targets1 for migraine prevention than the ≥50% reduction in monthly migraine days (MMDs) typically used to assess treatment response, comes from an observational study of 62 patients followed up at a tertiary migraine centre in Portugal.2 Most patients were treated with …
Read more »The efficacy of a once-daily (QD) dose of rimegepant 75 mg appears more robust than the current every other day (EOD) dosing regimen for prevention of episodic migraine, conclude investigators for a large, placebo-controlled trial of the efficacy and safety of the two dosing regimens (NCT05217927). In the multicentre study, 699 patients were randomised to …
Read more »Elevated baseline plasma CGRP and interleukin 1β (IL-1β) expression have shown promise in helping to identify patients more likely to benefit from erenumab. Data from the BIOMIGA project (NCT04503083) in 164 participants, 38% with chronic migraine (CM), and 62% with highly frequent episodic migraine (HFEM), were reported at the congress. Median monthly headache days (MHDs) …
Read more »Clinical trial participants are likely to spontaneously talk about common migraine symptoms but need more probing questions to report cognitive symptoms, according to results of interviews with 50 participants in the Phase 2 HOPE trial of the anti-PACAP mAb, Lu AG09222. Optional, semi-structured interviews were conducted up to 14 days after the safety follow-up visit …
Read more »Preliminary findings from the ATOM project (NCT06882122) have shown that clinical improvement in response to atogepant in patients with high-frequency episodic migraine (HFEM) is associated with modulation of the endocannabinoid system and specific microRNAs (miRNAs). In the prospective study involving 18 patients with HFEM (8–14 migraine days per month [MMDs]) treated with daily atogepant 60 …
Read more »Real-world experience of galcanezumab use for chronic migraine (CM) prevention at a UK migraine clinic has confirmed that few responders can achieve remission and most relapse if they stop treatment. In the study, 125 patients with CM (mean age 42.5 years [range 21-75]) started galcanezumab between January and May 2022. They had failed an average …
Read more »A post hoc analysis from the PEARL study (EUPAS35111) has shown that patients taking fremanezumab at early disease stages may have better migraine outcomes than those who wait for the CGRP mAb until they have chronic migraine (CM) or have failed on three other types of treatment. In the analysis of data from 1,128 patients …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
